SCHEMBL29802436

SCHEMBL29802436

CC(CCNc1nc(NC(C)(C)C)ncc1N)NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
CCNE2 O96020 1/20 0.36
CCNA2 P20248 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 2/20 0.35
IRAK4 Q9NWZ3 2/20 0.34
MAPK8 P45983 2/20 0.34
MAPK9 P45984 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
MAPK10 P53779 1/20 0.34
TRPA1 O75762 1/20 0.33
P2RY2 P41231 1/20 0.33
MERTK Q12866 1/20 0.33
CA2 P00918 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29802703 0.84 MAPK8 (0.42) MAPK8MAPK9MERTKSYK
SCHEMBL29802501 0.84 PRKCQ (0.38) STK17BSTK17ACCNE2CCNA2CCNE1
SCHEMBL19665726 0.82 STK17B (0.56) STK17BSTK17AMERTKCA2CA1
SCHEMBL29802472 0.82 STK17B (0.56) STK17BSTK17AMERTKCA2CA1
SCHEMBL28639902 0.80 JAK3 (0.38) JAK2JAK1TYK2JAK3MAPK8
SCHEMBL29290148 0.79 LATS1 (0.44) STK17BSTK17AMAPK8MAPK9ADORA3
SCHEMBL29290164 0.76 JAK2 (0.34) JAK2JAK1TYK2JAK3MAPK8
SCHEMBL29802475 0.74 ACACB (0.42) CCNE2CCNA2CCNE1CDK2CCNA1
SCHEMBL28652855 0.73 JAK3 (0.38) STK17BSTK17AJAK2JAK1TYK2
SCHEMBL19665693 0.72 SIRT5 (0.41) STK17BSTK17AMAPK8MAPK9ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464287-B1 ANIMAL AND HUMAN ANTI-MALARIAL AGENTS CELGENE CORP (US) 2022-06-08 EP disclosed
US-11344554-B2 Animal and human anti-malarial agents CELGENE CORPORATION (US) 2022-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344554-B2 Animal and human anti-malarial agents HPRT1, UMPS, PNP STK17B 3629/4885STK17A 3295/4885CCNE2 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.